AN2 Therapeutics director granted 11,560 ANTX shares

AN2 Therapeutics director Gilbert Lynn Marks reported a stock-based compensation grant of 11,560 shares of common stock on January 12, 2026.

Rhea-AI Filing Summary

AN2 Therapeutics director Gilbert Lynn Marks reported a stock-based compensation grant of 11,560 shares of common stock on January 12, 2026. The shares were issued at a price of $0.00 per share under the company’s non-employee director compensation policy, in lieu of cash fees. According to the disclosure, all of these shares vest immediately.

Following this transaction, Marks directly beneficially owns 75,309 shares of AN2 Therapeutics common stock. The filing characterizes this as a routine equity grant for board service rather than an open-market purchase or sale.

Insider Trade Summary

Grant/Award: 11,560 shares

Grant/Award 1 txn

Insider Marks Gilbert Lynn

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	11,560	$0.00	$0.00

Holdings After Transaction: Common Stock — 75,309 shares (Direct)

Footnotes (1)

1. F1. Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did AN2 Therapeutics (ANTX) report for Gilbert Lynn Marks?

The company reported that director Gilbert Lynn Marks received 11,560 shares of common stock on January 12, 2026 as a stock grant.

How many AN2 Therapeutics (ANTX) shares does Gilbert Lynn Marks hold after this Form 4 transaction?

After the reported transaction, Gilbert Lynn Marks beneficially owns 75,309 shares of AN2 Therapeutics common stock directly.

What was the price per share for the AN2 Therapeutics stock granted to Gilbert Lynn Marks?

The 11,560 shares of AN2 Therapeutics common stock were issued at a reported price of $0.00 per share as compensation, not a market purchase.

Why did AN2 Therapeutics grant 11,560 shares to director Gilbert Lynn Marks?

The shares were granted in lieu of cash compensation under AN2 Therapeutics' non-employee director compensation policy.

Do the AN2 Therapeutics shares granted to Gilbert Lynn Marks vest over time?

No. According to the disclosure, all 11,560 shares vest immediately upon grant.

Is Gilbert Lynn Marks a director or officer of AN2 Therapeutics (ANTX)?

Gilbert Lynn Marks is reported as a director of AN2 Therapeutics and not as an officer or 10% owner in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/14/2026 - 05:06 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Marks Gilbert Lynn

(Last) (First) (Middle)

C/O AN2 THERAPEUTICS, INC.

1300 EL CAMINO REAL, SUITE 100

(Street)

MENLO PARK CA 94025

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AN2 Therapeutics, Inc. [ ANTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/12/2026		A		11,560(1)	A	$0	75,309	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately.

	/s/ Lucy Day, Attorney-in-Fact for Gilbert Lynn Marks	01/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.